[Cinnabarinic acid as a potential prognostic marker of schizophrenia].

Autor:	Shilov YE; Mental Health Research Center, Moscow, Russia., Baymeeva NV; Mental Health Research Center, Moscow, Russia., Brusov OS; Mental Health Research Center, Moscow, Russia., Oleichik IV; Mental Health Research Center, Moscow, Russia., Sizov SV; Mental Health Research Center, Moscow, Russia., Tyurin IA; Sklifosovsky Research Institute of Emergency Medicine of Department of Health of Moscow, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2022; Vol. 122 (12), pp. 138-142.
DOI:	10.17116/jnevro2022122121138
Abstrakt:	Objective: To develop a method for determining cinnabarinic acid (CA) and its immediate precursor 3-hydroxyanthranylic acid (3HAA) in blood plasma and to study their concentrations in patients with schizophrenia before and after treatment. Material and Methods: The study was carried out on a sample of 23 female patients with an attack-like progredient schizophrenia (F20.01). The levels of CA and 3HAA in blood plasma were measured using liquid chromatography with tandem mass spectrometry. Results: We found an inverse statistically significant correlation of the sum of CA and 3HAA concentrations before treatment with the total PANSS score after treatment (R=-0.50; p <0.05). There was also an inverse correlation of the CA concentration of before treatment with the total PANSS score after treatment (R=-0.41, p= 0.052), statistically significant at the trend level (0.05< p <0.1). Conclusion: CA concentrations in human blood were determined for the first time. The obtained correlations with clinical data show the potential prognostic significance of determining the levels of CA and 3HAA in blood plasma and increase the relevance of further studies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu